Medical Principles and Practice

Original Paper

Free Access

Comparison of Antimicrobial Resistance of Acinetobacter baumannii Clinical Isolates from Shanghai and Hong Kong

Ling T.K.W.a · Ying C.M.b · Lee C.C.a · Liu Z.K.a

Author affiliations

aDepartment of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, SAR, and bDepartment of Microbiology, Shanghai Second Medical University, Renji Hospital, Shanghai, China

Corresponding Author

Dr. Thomas K.W. Ling

Department of Microbiology, The Chinese University of Hong Kong

Prince of Wales Hospital

Hong Kong, SAR (China)

Tel. +852 26322307, Fax +852 26451256, E-Mail lingt@cuhk.edu.hk

Keywords: Antimicrobial resistanceAcinetobacter baumanniiShanghaiHong Kong

Related Articles for ""
Med Princ Pract 2005;14:338–341
https://doi.org/10.1159/000086932

Abstract

Objective: To compare the antimicrobial resistance patterns of Acinetobacter baumannii isolates from Shanghai and Hong Kong. Materials and Methods: A total of 212 A. baumannii strains of one isolate per patient were collected from Shanghai and Hong Kong from August 2002 to August 2003 that were tested against 15 commonly used antimicrobial agents by the agar dilution method according to the NCCLS guidelines. Results: Most β-lactams showed no significant increase in activity after adding β-lactamase inhibitors. The resistance rates of the isolates against ticarcillin-clavulanate, piperacillin-tazobactam and ampicillin-sulbactam were for Shanghai 74.9, 70.9, 69.1% and Hong Kong 24.3, 18.9, 13.5%, respectively. Only cefoperazone-sulbactam showed a significant increase in activity against both Shanghai and Hong Kong strains, as the resistance rates dropped from 93.7 to 8.6% and 83.8 to 5.4%, respectively. The resistance rates of ceftazidime, cefepime, and gentamicin against Shanghai strains were 69.7, 72.0, 73.7% and Hong Kong strains 69.7, 29.7, 18.9%, respectively. About 65% of Shanghai strains were found to be amikacin-resistant, however, all Hong Kong strains were sensitive. Fluoroquinolones including ciprofloxacin and levofloxacin had resistance rates over 60% against Shanghai strains, but only 13.5% against Hong Kong strains. Shanghai strains had imipenem and meropenem resistance rate of 6.3%. Though 10.8% Hong Kong strains were resistant to meropenem, only 2.7% of them were resistant to imipenem. Conclusion:A. baumannii isolated from Shanghai were more resistant to all drugs except meropenem than Hong Kong isolates. The results indicate a need for measures to control the abuse of antibiotic usage in order to prevent the emergence of more multidrug-resistant isolates in both cities.

© 2005 S. Karger AG, Basel



Related Articles:

References

  1. Theaker C, Azadian B, Soni N: The impact of Acinetobacter baumannii in the intensive care unit. Anaesthesia 2003;58:271–274.
    External Resources
  2. El Shafie SS, Alishaq M, Leni Garcia M: Investigation of an outbreak of multidrug-resistant Acinetobacter baumannii in trauma intensive care unit. J Hosp Infect 2004;56:101–105.
    External Resources
  3. Herruzo R, de la Cruz J, Fernandez-Acenero MJ, Garcia-Caballero J: Two consecutive outbreaks of Acinetobacter baumannii 1-a in a burn Intensive Care Unit for adults. Burns 2004;30:419–423.
    External Resources
  4. Rello J: Acinetobacter baumannii infections in the ICU: customerization is the key. Chest 1999;115:1226–1229.
    External Resources
  5. Jones ME, Thornsberry C, Livermore DM, Sahm DF: Prevalence of Acinetobacter spp. isolates with reduced sensitivity to imipenem, as determined by a USA-wide electronic surveillance network. J Antimicrob Chemother 1999;43:429–431.
    External Resources
  6. Afzal MS, Livermore DM: Worldwide emergence of carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 1998;41:576–577.
    External Resources
  7. Ling JM, Ng TK, Cheng AF, Norrby SR: Susceptibilities to 23 antimicrobial agents and beta-lactamase production of blood culture isolates of Acinetobacter sp. in Hong Kong. Scand J Infect Dis 1996;101:21–25.
    External Resources
  8. Murray PR, Barron EJ, Pfaller MA, Tenover FC, Yolken RH (eds): Manual of Clinical Microbiology, ed 7. Washington, American Society for Microbiology, 1999.
  9. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, ed 4. Approved standard M7-A4. Wayne, National Committee for Clinical Laboratory Standards, 1997.
  10. Bergogne-Berezin E, Towner KJ: Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996;9:148–165.
    External Resources
  11. Berlau J, Aucken HM, Malnick H, Pitt TL: Distribution of Acinetobacter spp. on skin of healthy humans. Eur J Clin Microbiol Infect Dis 1999;18:179–183.
    External Resources
  12. Cisneros JM, Reyes MJ, Pachon J, Becerril B, Caballero FJ, Garcia-Garmendia JL, Ortiz C, Cobacho R: Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996;22:1026–1032.
    External Resources
  13. Husni RN, Goldstein LS, Arroliga AC, Hall GS, Fatica C, Stoller JKG, Gordon SM: Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients. Chest 1999;115:1378–1382.
    External Resources
  14. Wisplinghoff H, Perbix W, Seifert H: Risk factors for nosocomial bloodstream infections due to Acinetobacter baumannii: a case-control study of adult burn patients. Clin Infect Dis 1999;28:59–66.
    External Resources
  15. Timsit JF, Garrait V, Misset B, Goldstein FW, Renaud B, Carlet J: The digestive tract is a major site for Acinetobacter baumannii colonization in intensive care unit patients. J Infect Dis 1993;168:1336–1337.
    External Resources
  16. Dy ME, Nord JA, Labombardi VJ, Kislak JW: The emergence of resistant strains of Acinetobacter baumannii: clinical and infection control implications. Infect Control Hosp Epidemiol 1999;20:565–567.
    External Resources
  17. Higgins PG, Wisplinghoff H, Stefanik D, Seifert H: In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multi-drug resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother 2004;48:1586–1592.
    External Resources
  18. Wang FD, Lin ML, Lee WS, Liu CY: In vitro activities of beta-lactam antibiotics alone and in combination with sulbactam against Gram-negative bacteria. Int J Antimicrob Agents 2004;23:590–595.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: July 31, 2004
Accepted: November 27, 2004
Published online: August 18, 2005
Issue release date: September – October

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 1

ISSN: 1011-7571 (Print)
eISSN: 1423-0151 (Online)

For additional information: https://www.karger.com/MPP

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2005, Vol.14, No. 5

September – October

Article

Recommend This
Open Access Gateway
TOP